Investigation of histone demethylase JMJD1A in diabetic retinopathy

2019 Fiscal Year Final Research Report

• Project/Area Number: 18K16941
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56060:Ophthalmology-related
• Research Institution: St. Marianna University School of Medicine
• Principal Investigator: shiono akira 聖マリアンナ医科大学, 医学部, 講師 (20737598)
• Project Period (FY): 2018-04-01 – 2020-03-31
• Keywords: jmjd1a / 糖尿病網膜症

Outline of Final Research Achievements

We investigated the difference of retinal vascular growth under normoxia in JMJD1A-deficient and non-deficient mice. Image J angiogenesis analyzer (Carpentier, 2012) was used to compare the vascular density and vascular total length at postnatal day 5, day 8, and 5 weeks, but there was no significant difference.
Next, JMJD1A-deficient and non-deficient mice were exposed to increased oxygen levels cage to make Oxygen-Induced Retinopathy (OIR) model and we quantify neovascularization in the retina. As a result, low neovascularization was observed in JMJD1A-deficient mice than non-deficient mice and there was statistically significant difference. Although there was no significant difference in the vaso-obliteration area, a decrease tendency was observed in the JMJD1A-deficient mice.

Free Research Field

眼科　血管新生

Academic Significance and Societal Importance of the Research Achievements

近年、糖尿病網膜症や滲出型加齢黄斑変性を始めとする血管新生、血管透過性亢進を病態とする網脈絡膜疾患に対する治療薬として、VEGF阻害薬が広く使用されている。しかしながら、効果が不十分であったり、短期間しか効果が得られない症例も多く存在する。JMJD1Aはヒストン脱メチル化酵素として知られていたが、近年、腫瘍領域でVEGFとは異なるメカニズムで血管増殖に関与していることが示された。私たちは網膜血管におけるJMJD1Aの機能解析を行い、VEGF阻害薬とは異なるメカニズムからのアプローチにより新規治療法の開発を目指す。